Table 1.
Formulation | Progestin | Progestin mg/day (days dosage) | Ethinyl Estradiol mg/day (days dosage) | Generationc |
---|---|---|---|---|
A | levonorgestrel | 0.100 (21) | 0.020 (21) | 2nd |
B | norethindrone acetate | 1.000 (24) | 0.020 (24) | 2nd |
C | desogestrel | 0.150 (21) | 0.020 (21) | 3rd |
0.010 (5) | ||||
D | norgestimate | 0.250 (21) | 0.035 (21) | 2nd |
Ea | norgestimate | 0.180 (7) | 0.025 (21) | 2nd |
0.215 (7) | ||||
0.250 (7) | ||||
F | drospirenone | 3.000 (21) | 0.030 (21) | 4th |
Ga | drospirenone | 3.000 (24) | 0.020 (24) | 4th |
–b | norethindrone acetate | 1.5 (21) | 0.030 (21) | 2nd |
–b | norethindrone acetate | 0.350 (continuous) | – | 2nd |
–b | norgestimate | 0.180 (7) | 0.035 (21) | 2nd |
0.215 (7) | ||||
0.250 (7) | ||||
–b | etonogestrel vaginal ring | 0.120 (continuous) | 0.015 (continuous) | |
–b | desogestrel | 0.150 (21) | 0.030 (21) | 3rd |
Not included in UHS list of commonly prescribed contraceptives but included in analysis.
Not included in analysis due to lack of pharmacokinetic information in the package inserts.
Generation identified based on criteria in Golobof and Kiley [28].